Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could EMDR therapy help calm the Brain's faulty signals?

NCT ID NCT05455450

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested whether a therapy called EMDR (eye movement desensitisation and reprocessing) could help people with functional neurological disorder (FND), a condition where the brain doesn't send signals properly, causing symptoms like seizures, shaking, or weakness. Fifty adults with FND were randomly assigned to receive either EMDR plus routine care or routine care alone. The goal was to see if a larger trial is possible, not to prove the therapy works yet.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Eye movement desensitisation and reprocessing (EMDR) therapy
What this could lead to
If successful, this could point toward a new psychological treatment option for people with functional neurological disorder, potentially easing symptoms like seizures and weakness.
What could go wrong
This is a very early feasibility study with only 50 participants, not designed to prove effectiveness. The therapy may not work for everyone, and larger trials are needed to confirm any benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

50 people

The number who actually took part.

Started

Nov 2022

Finished

May 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Predominant diagnosis of functional seizures and/or functional motor disorder, with diagnosis confirmed by neurologist 2. Aged 18 years or over 3. Capacity to consent 4. Willingness to attend regular psychological therapy sessions 5. Reporting at least 1 traumatic event on the International Trauma Exposure Measure Exclusion Criteria: 1. Non-English speaking 2. Current ongoing adversity that is likely to interfere with psychological therapy, e.g. domestic violence, homelessness, unresolved compensation claim/litigation 3. Predominant diagnosis of Borderline Personality Disorder\* 4. Predominant diagnosis of chronic pain condition\*, e.g. fibromyalgia 5. Predominant diagnosis of chronic fatigue syndrome\* 6. Diagnosis of a psychotic disorder 7. Diagnosis of Dissociative Identity Disorder or score in clinical range on "identity disturbance" subscale of Multiscale Dissociation inventory 8. Uncontrolled epileptic seizures 9. Diagnosis of an eating disorder 10. Current severe self harm or strong suicidal ideation that requires secondary care mental health services input 11. Current alcohol or drug harmful-use or dependence 12. Current diazepam use exceeding the equivalent of 10mg per day 13. Currently attending individual psychological therapy focused on functional neurological disorder or other specialist functional neurological disorder-specific treatment such as inpatient/outpatient multi-disciplinary treatment or intensive functional neurological disorder-specific physiotherapy * Comorbid diagnosis is acceptable, as long as functional neurological disorder is the predominant difficulty

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Functional neurological symptom disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Neuropsychiatry Service

    London, SW170QT, United Kingdom

  • South West London & St George's NHS Trust

    London, SW17 7DJ, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.